[Therapy of paraproteinemic diseases].
D000493:Allopurinol / Q000627:therapeutic use; D000731:Androstanes / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001798:Blood Proteins / Q000032:analysis; D003520:Cyclophosphamide / Q000008:administration & dosage; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D010954:Plasmacytoma / Q000188:drug therapy* / Q000532:radiotherapy; D011241:Prednisone / Q000627:therapeutic use; D011507:Proteinuria
D000731:Androstanes; D000970:Antineoplastic Agents; D001798:Blood Proteins; D005938:Glucocorticoids; D000493:Allopurinol; D003520:Cyclophosphamide; D008558:Melphalan; D011241:Prednisone
Die Therapie paraproteinämischer Erkrankungen.